Vitality Watch

Dossier pubmed preclinical 05-aug-2026
Animal model, organoid, or cell-culture result — not yet human

Hepatic SIRT6 Deficiency Accelerates Female-Specific Aging Through SULT1E1-Mediated Estrogen Depletion.

Key claim: Hepatocyte-specific SIRT6 deficiency accelerates female aging and cuts median lifespan by ~17.6% through SULT1E1-driven estrogen depletion, while the SIRT6 activator MDL-800 restores estrogen homeostasis and rescues gerometabolic phenotypes in aged female mice.

Abstract

Sexual dimorphism is a fundamental feature of aging, yet the liver-centric mechanisms underlying sex-specific aging trajectories remain incompletely understood. SIRT6, a NAD-dependent deacetylase, is a master regulator of genome stability, metabolic homeostasis, and longevity. However, its cell-type- and sex-specific functions in aging have not been fully characterized. Here, we generated hepatocyte-specificknockout (HKO) mice of both sexes and evaluated longitudinal lifespan, comprehensive metabolic profiling, hepatic histopathology, and transcriptomic profiles. Female HKO mice exhibited an acceleration of aging and a 17.60% reduction in median lifespan, characterized by severe systemic gerometabolic decline, visceral adiposity, and advanced metabolic-associated fatty liver disease (MAFLD). In stark contrast, aged male HKO mice displayed an enhanced catabolic state and lipid-clearing phenotype via the compensatory reprogramming. Mechanistically, hepaticdeficiency in females exclusively hyperactivated the expression of estrogen sulfotransferase SULT1E1, resulting in reduced circulating estradiol levels. This hormonal collapse triggered a self-amplifying pathological triad of de novo lipogenesis, genomic instability, and cellular senescence. Crucially, pharmacological SIRT6 activation using the small-molecule activator MDL-800 suppressedexpression, restored estrogen homeostasis, and successfully rescued the gerometabolic phenotypes in aged female mice. Collectively, these findings demonstrate that hepatic SIRT6 regulates female lifespan and healthspan by safeguarding estrogen homeostasis, defining the druggable SIRT6-SULT1E1 axis as a sex-stratified therapeutic target against age-related metabolic decline.

Why this matters

Female aging biology is dominated by ovarian-decline framings, but this work localizes a substantial fraction of estrogen homeostasis to hepatocyte SIRT6 gating of SULT1E1-mediated estrogen sulfation, and shows that pharmacologic SIRT6 activation (MDL-800) can restore estrogen and gerometabolic phenotypes in aged female mice. If the axis translates, it opens a non-ovarian, non-HRT lever on the menopause-as-aging-driver frame and gives the SIRT6 activator pipeline a sex-stratified indication — but the ~17.6% lifespan effect is mouse-only and depends on a hepatocyte-specific knockout, so the biology sits well ahead of any human claim.

Source

Link

Briefing card

Hepatic SIRT6 Deficiency Accelerates Female-Specific Aging Through SULT1E1-Mediated Estrogen Depletion.
Stage: preclinical · pubmed · 05-aug-2026

Hepatocyte-specific SIRT6 deficiency accelerates female aging and cuts median lifespan by ~17.6% through SULT1E1-driven estrogen depletion, while the SIRT6 activator MDL-800 restores estrogen homeostasis and rescues gerometabolic phenotypes in aged female mice.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.3390/ijms27157039

build build 880 · 2bcef25 · 2026-11-18